Paula Rodriguez-Otero

48PUBLICATIONS
288CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical mycologyHaematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (48)

|Oct 02, 2026
A myeloid-dormant metabolic transcriptome identifies a poor-prognosis subgroup in hyperdiploid multiple myeloma with targetable vulnerabilities.

|Sep 30, 2026
Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.

|Sep 02, 2026
Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

|Aug 06, 2026
Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study.

|Jul 24, 2026
MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

|Jul 02, 2026
Multiple myeloma: A tale of deregulated transcription factors.

Pageof 8

Frequent Collaborators

22 joint publications

María-Victoria Mateos

20 joint publications

Bruno Paiva

19 joint publications

Jesus San-Miguel

14 joint publications

Laura Rosiñol